key: cord-0908055-xvr5nzwp
authors: Kolude, Olufunmilola; Emmanuel, Eyitayo E; Aibinuomo, Ayomide O; Ipinnimo, Tope M; Ilesanmi, Mary O; Adu, John A
title: Assessment of the Quality of COVID-19 Antigen Rapid Diagnostic Testing in the Testing Sites of Ekiti State, Nigeria: A Quality Improvement Cross-Sectional Study
date: 2022-04-16
journal: Cureus
DOI: 10.7759/cureus.24173
sha: 007d941af1ae00b55181be0ee0fffec6c36d5f1a
doc_id: 908055
cord_uid: xvr5nzwp

Background Antigen rapid diagnostic testing (Ag-RDT) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important testing technique used for the control and containment of COVID-19. This study aims to assess the quality of COVID-19 Ag-RDT in the testing sites in Ekiti State, Nigeria. Methods A validated World Health Organization (WHO) questionnaire was used to collect data from 138 testing sites located in 138 health facilities in Ekiti State. The assessment was based on the activities carried out in the last three months before the study. Results A total of 138 testing sites participated in the study out of which 121 (87.7%) were primary health facility testing sites. The mean number of samples tested in these sites was 26 samples, and 97 (70.3%) testing sites were tested below this. The average quality performance of the secondary/tertiary health facility testing sites (64.46 ± 10.47) was significantly higher than that of the primary health facility testing sites (53.13 ± 13.54) (p = 0.002). Additionally, the average quality performance of testing sites that tested 26 samples or more (61.61 ± 9.84) was significantly higher than that of the testing sites that tested below this mean cut-off (51.53 ± 13.97) (p < 0.001). Conclusion The majority of the testing sites that tested below the mean 26 samples, secondary/tertiary health facility testing sites, and sites that tested above the mean cut-off had higher average quality performance scores. Therefore, encouraging clinicians to refer for more testing of suspected cases and supportive supervision of COVID-19 Ag-RDT, especially in primary health facilities, is recommended.

Coronavirus disease 2019 (COVID-19) is a new disease that was detected when the Chinese authorities and the World Health Organization (WHO) became aware of a cluster of pneumonia cases with unknown etiology in Wuhan in December 2019 [1] [2] [3] . The disease was declared to be caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in January 2020 and was declared a disease of public health emergency of international concern (PHEIC) [1, 2, 4] . The virus belongs to the beta-corona virus genera and preferentially infects cells of the respiratory tract, but its organotropism to areas such as the brain, conjunctiva, pharynx, lungs, heart, liver, and kidney is not well understood [5] .

COVID-19 has continued to be a worldwide challenge. Contact reduction and tracing, quarantine, vaccination, early detection, and treatment are key strategies to reduce the spread of the disease [6] . Testing remains a clinical tool, and it is a part of the first-line defense against COVID-19 as it enables early identification and isolation of cases, which helps slow down the disease transmission and helps target clinical care to those infected with overall protection of the health system [7, 8] .

At the inception of COVID-19 disease, the WHO recommends nucleic acid amplification test (NAAT) for identification of COVID-19 infection, but the test requires sophisticated laboratory infrastructures and 1 1 1 2, 1 skilled personnel [1, 3] . Taking a nasopharyngeal swab, followed by a transcription-polymerase chain reaction of extracted ribonucleic acid is the recommended gold standard for the detection of SARS-CoV-2 [5] . Though numerous COVID-19 testing using the above technique have been performed globally, the demand for testing a large number of patients, more timely testing, and more accurate testing continues to exceed the testing capacity [3, 5] . Also, technicality and the financial burden remain a challenge for this testing technique [5] . Furthermore, with the situation in the sub-Saharan African and low-income countries where molecular testing is mainly available in central reference laboratories with limited testing capacity, there emerged the need for a test technique to deal with the constraints of testing capacity, reduce backlogs, and ensure that patients with urgent clinical needs are prioritized [1, 9] .

Antigen rapid diagnostic testing (Ag-RDT) for SARS-CoV-2 is seen as an important testing technique to fight the spread of COVID-19 infection [3] . The Ag-RDT works by detecting antigens, and its accuracy depends on factors such as viral load in the specimen, quality of the sample, and the time from the onset of the infection [8] . Though the sensitivity of Ag-RDT is lower than NAAT, it has the advantages of lower cost and rapid result output [1, 8] . The Ag-RDT is more simple, user-friendly, equipment-free, and can be operated safely at the point of care; the result is usually straightforward and quick [1, 5, 8] .

Rapid diagnostic test supports the control of infection in both hospital and community settings [5] . It will allow expansion of testing access, enable accurate estimation of disease burdens, and help in achieving the targets of control measures and treatments [2, 7] . The Ag-RDT for COVD-19 has been in operation in the Ekiti State, and this study aims to assess the quality of testing in the testing sites of Ekiti State, Nigeria. The testing sites are located in health facilities in all the senatorial districts and LGAs of the state. There were 141 testing sites located in 141 health facilities across the state at the time of this study, but only 138 of these testing sites/health facilities could be visited and assessed. The other three sites were not assessed due to security challenges in areas where they were located at the time when the survey was ongoing. The laboratory technicians at the testing sites were interviewed using a validated, interviewer-administered structured questionnaire between the 26th and 30th of August, 2021, and the assessment was based on the activities carried out in the last three months before the study. The content of the questionnaire was adopted from the Stepwise Process for Improving the Quality SARS-CoV-2 Antigen Rapid Diagnostic Testing (SPI-RT) checklist, which is based on the WHO assessment tool for laboratories implementing COVID-19 virus testing (Interim guidance: October 2020), and its format and layout were adapted from the SPI-RT checklist (stepwise) [11] . The questionnaire has sections on characteristics of the testing site, documents and records, personnel training and certification, safety, physical infrastructure, pre-testing phase, testing phase, post-testing phase, and external quality assessment (EQA).

Medical doctors and laboratory scientists were trained by the researchers for four hours a day on the data collection tools, techniques, and procedures as research assistants. The questionnaire was uploaded on open data kit (ODK) software and was used in the collection of data. The ODK had a global positioning system (GPS) tracker on it to ascertain that the research assistants visited the testing sites.

Data collected was downloaded from the ODK server created for the survey and later analyzed using the Statistical Package for the Social Science (SPSS) for Windows version 23.0 (IBM Corp., Armonk. NY). The questionnaire contains questions under each section with options of "yes," "partial," or "no." Questions marked "yes" receive one point each; those marked "partial" receive 0.5 points each, and those marked "no" receive zero points each. However, some questions under the section of EQA were marked with "not applicable" ("NA") in addition to "yes," "partial," and "no." For every item marked "NA" in this section, the equivalent points are deducted from the expected total possible points. Total points scored for each section were tallied and recorded at the end of the section and expressed as a percentage of the total possible score of that section. The overall average percentage score from all eight sections was obtained as the average quality performance score for the testing sites.

Testing sites were grouped based on testing capacity and also based on the type of healthcare facility where they are located (primary, secondary, and tertiary). The tertiary healthcare facility was later grouped with secondary health facilities during the analysis because there was only one tertiary health facility with a testing site. Frequency, percentages, mean, and standard deviation were presented in tables at the univariate level of analysis. An independent student t-test was used to compare the average quality score between the two groups. p < 0.05 was taken as the significant value.

Ethical approval was sought and obtained from the Research and Ethics Review Committee of Federal Teaching Hospital, Ido-Ekiti, Ekiti State, Nigeria (Protocol number: ERC/2021/08/04/694B). Permission and consent for the study were taken from the heads of all the health facilities involved in the study.

A total of 138 testing sites participated in the study. Table 1 shows that out of the 138 testing sites, 121 (87.7%) were located in primary health facilities, 16 (11.6%) were located in secondary health facilities, and one (0.7%) was located in a tertiary health facility. The mean number of samples tested by the sites was 26 samples. More than two-thirds (70.3%) of the testing sites were tested below the mean sample cut-off, while 41 (29.7%) testing sites tested 26 samples and above. Table 3 shows that the average quality performance of the secondary/tertiary health facility testing sites (64.46 ± 10.47) was higher than that of the primary health facility testing sites (53.13 ± 13.54) (p = 0.002). The secondary/tertiary health facility testing sites had a significantly higher average score than the primary health facility testing sites in sections of documentation and records ( However, there was no significant difference in the section on documentation and records, personnel training and certification, and testing phase between the testing sites that tested above the mean sample and below the mean sample.

COVD-19 Ag-RDT testing mainly occurred in primary healthcare facilities in comparison to the secondary and tertiary testing sites in the state. This may be because Ekiti State and Nigeria at large operate a ward health system where each ward has at least a primary health facility [12] . In addition, the requirement for the establishment of a primary health facility is much lesser than the secondary and tertiary health facilities.

Primary healthcare facilities are also the first points of access to health care for the majority of inhabitants of communities.

More than three-quarters of the testing sites tested below the mean samples. This lower testing rate by the testing sites may be due to low patient patronage of the primary healthcare facilities as well as the community apathy toward COVID-19 testing as the majority of Ekiti inhabitants believed they were unlikely to get infected with COVID-19 [13] .

The secondary/tertiary health facility testing sites did better than the primary health facility testing site in terms of the overall quality performance. This may be due to the availability of better infrastructures in terms of adequate space for testing, ventilation, and good lighting as well as better-skilled manpower in the secondary and tertiary health facilities than those in the primary health centers [14] . Also, the secondary/tertiary health facility testing sites were significantly better in sections of documentation and records, physical infrastructure, safety, pre-testing phase, post-testing phase as well as EQA. However, the primary health facility testing sites did better in the areas of the testing phase and personnel training and certification. Although this was not statistically significant, it may be because Ag-RDT testing is userfriendly, equipment-free, and easily operated at the point of care [1, 5, 8] .

Furthermore, testing sites that tested above the testing mean cut-off did better in the quality assessment than those sites testing below the mean cut-off. The reason for this finding may be because testing sites that test above the mean cut-off have a better testing capacity and also get better with more testing. It was difficult to compare results as the literature search revealed no previous study that assesses the quality of Ag-RDT testing of COVID-19. COVID-19 is a new disease with so many uncertainties; however, several scientific research is still ongoing to unravel these. The limitation of this study was that all testing sites could not be assessed due to security compromises during the period of data collection.

The majority of the testing sites tested below the mean 26 samples; secondary/tertiary health facility testing sites had better average testing performance than the primary health facility testing sites. Also, sites that tested more had higher average quality performance scores than those that tested less. Therefore, encouraging clinicians to refer for more testing and supportive supervision of COVID-19 Ag-RDT is recommended especially in primary health facility testing sites.

Stepwise process for improving the quality of SARS-CoV-2 antigen rapid diagnostic testing (SPI-RT) checklist (March 2021)

The stepwise process for improving the quality of the SARS-CoV-2 antigen rapid diagnostic testing (SPI-RT) checklist is based on the WHO assessment tool for laboratories implementing COVID-19 virus testing (Interim Guidance: October 2020), and its format and layout were adapted from the SPI-RT checklist. It is intended to be used by supervisors, mentors, internal or external auditors undertaking testing site assessments or supervision visits in support of the implementation of quality assurance aspects of the SARS-CoV-2 antigen rapid testing. Site assessments or supervisions should be undertaken by trained persons that are responsible for supporting SARS-CoV-2 Ag-RDT rollout and implementation. The assessment findings should provide opportunities for improvement to SARS-COV-2 testing sites with the aim of ensuring the provision of quality COVID-19 Ag-RDT results. At a minimum, site assessments and/or supervision visits should be performed periodically, at least quarterly. However, more frequent visits should be arranged, particularly when a new test kit is introduced, a site is new, when there are new guidelines, or when many non-conformances are identified at the testing site.

In cases where the assessment report from the most recent visit is available, it should be reviewed prior to the supervision visit. During the visit, actions that were identified to address the areas of weakness during the previous visit must be reviewed and checked for completeness. After the support supervision, an on-site debriefing meeting should be conducted immediately before leaving the facility using the draft supervision report at hand. A final report, including supervision/assessment findings and the feedback from the debrief meeting and all relevant documents should be shared with the facility, Ministry of Health focal point, supporting implementing partner within one week. The supervised/assessed testing facility is required to develop and implement a corrective and preventive action plan to address all the non-conforming areas. In cases where the testing facility meets the required quality assurance requirements, effort should be made to maintain and sustain the quality management system.

Before completing the checklist, it is important to characterize the testing point to be audited. Please provide relevant information in the summary 

For each of the sections listed below, please indicate a response Yes, Partial, or No against each requirement/question. Indicate "Yes" only when all elements are satisfactorily present. Provide comments for each "Partial" or "No" response. For each "Yes" response, award a score of one point in the adjacent cell;

for Partial, award 0.5 points, and for No, a zero-point score is awarded. State N/A in the comments section if "not applicable" where appropriate (*).

Are the following guidelines specific for SARS-CoV-2 antigen rapid diagnostic testing available at the testing facility? 6.2 Is the testing area clean and organized for SARS-CoV-2 antigen rapid diagnostic testing?

6.3 Is sufficient lighting available in the designated testing area?

6.4 Are the SARS-CoV-2 Ag-RDT kits stored within the temperature range based on the manufacturers' instructions?

6.5 Is there sufficient and secure storage space for test kits and other consumables?

6.6 Is the space allocated for SARS-CoV-2 antigen rapid diagnostic testing adequate to perform the work without compromising the quality and safety of patients and testing personnel/health workers? 6.7 Is the COVID-19 sample collection area separated from the patient examination/testing areas/room(s)?

Physical facility scores attained Physical facility maximum possible score 7

Physical facility % score attained instruction: % score computation = scores attained divided by maximum possible score x 100% Safety % score attained instruction: % score computation = scores attained divided by maximum possible score x 100% Pre-testing phase % score attained instruction: % score computation = scores attained divided by maximum possible score x 100% Testing phase scores attained

Testing phase maximum possible score 9

Testing phase % score attained instruction: % score computation = scores attained divided by maximum possible score x 100% 11.10* Does the site collect swap samples for retesting according to country guidelines (e.g., collection of every 20 th client sample)?

11.11* Are the swap samples collected for retesting properly documented?

11.12* Are swap samples stored properly?

11.13* Are the identifier's samples sent for retesting properly recorded?

External quality audit scores attained External quality audit maximum possible score 13

External quality audit % score attained instruction: % score computation = scores attained divided by maximum possible score x 100% 

Human subjects: Consent was obtained or waived by all participants in this study. Human Research and Ethics Committee, Federal Teaching Hospital, Ido-Ekiti issued approval ERC/2021/08/04/694B. I fully understand the conditions under which I am authorized to conduct the above-mentioned research and I guarantee that I will ensure compliance with these conditions. Should any changes or departure be contemplated from the research procedure as approved, I undertake to re-submit the protocol to the Human Research and Ethics Committee for consideration and approval. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Implementing COVID-19 (SARS-CoV-2) rapid diagnostic tests in sub-Saharan Africa: a review

SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide

Using artificial intelligence to improve COVID-19 rapid diagnostic test result interpretation

Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis

Evaluation of SARS-CoV-2 antigenbased rapid diagnostic kits in Pakistan: formulation of COVID-19 national testing strategy

Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR

Interim guidance on the use of rapid antigen tests for COVID-19 response

A review of antigen-detecting rapid diagnostic tests for COVID-19

Guide to antigen testing for Sars-Cov-2 in South Africa

Antigen training package introduction and instructions

Primary health care system (PRIMASYS): case study from Nigeria

Ekiti State Government Ekiti State COVID-19 survey (EKCOVS) 2020: statewide household survey of prevalence, risk perception, adoption of preventive measures and people's understanding of COVID-19 in Ekiti State